Zydus Lifesciences Ltd share price was down by -0.64% from the previous closing price of ₹995.50. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare ... The newspaper publication of Notice of loss of share certificates of the Company published in the Financial Express English and ...

Nippon India Small Cap Fund (B) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (IDCW) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (G) 560.96 28,45,731 0.91 ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral Sclerosis (ALS), a rare neurodegenerative disease. New Delhi, Jan 22 (PTI) Zydus ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

Patel stated that he is fortunate to have 27,000 people at Zydus as a part of this journey working on putting India at the forefront of innovation with path-breaking discoveries that bridge unmet ...